uniQure to Participate in Upcoming Industry Conferences in October

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced its participation in several investor and scientific conferences, showcasing its advancements in gene therapy. Key events include Chardan's 6th Annual Genetic Medicines Conference from October 3-4, where a fireside chat with Dr. Ricardo Dolmetsch is scheduled. Additionally, at the European Society of Gene & Cell Therapy from October 11-14, uniQure will present preclinical data on various neurological diseases. Lastly, Dr. Dolmetsch will discuss Huntington's disease at the Latin American Huntington's Disease Conference from October 19-21.

LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

• Chardan’s 6^th Annual Genetic Medicines Conference, October 3 – 4, 2022
  
  
  • Members of uniQure’s management team, including Ricardo Dolmetsch, Ph.D., president of research and development, will participate in one-on-one investor meetings on Monday, October 3.
    
    
  • A fireside chat with Dr. Dolmetsch will take place the same day from 8:30 to 8:55 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Media section of the uniQure website.
    

• European Society of Gene & Cell Therapy (ESGCT), October 11 – 14, 2022
  
  
  • uniQure will present multiple preclinical data on its programs in temporal lobe epilepsy, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), along with key features of its AAV manufacturing process development. Specific details will follow when meeting abstracts are released.
    

• 2022 Latin American Huntington’s Disease Conference, October 19 – 21, 2022
  
  
  • Dr. Dolmetsch will present an overview of uniQure’s clinical development program of AMT-130 in Huntington’s disease on Thursday, October 20.
    

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com

uniQure Contacts:
FOR INVESTORS:		FOR MEDIA:
Maria E. Cantor	Chiara Russo	Tom Malone
Direct: 339-970-7536	Direct: 617-306-9137	Direct: 339-970-7558
Mobile: 617-680-9452	Mobile: 617-306-9137	Mobile:339-223-8541
m.cantor@uniQure.com	c.russo@uniQure.com	t.malone@uniQure.com

FAQ

What conferences will uniQure participate in October 2022?

uniQure will participate in Chardan's 6th Annual Genetic Medicines Conference, the European Society of Gene & Cell Therapy, and the Latin American Huntington's Disease Conference in October 2022.

Who will represent uniQure at the Chardan conference?

Dr. Ricardo Dolmetsch, the president of research and development, will represent uniQure at the Chardan conference during one-on-one investor meetings.

What will uniQure present at the European Society of Gene & Cell Therapy?

uniQure will present preclinical data on its programs related to temporal lobe epilepsy, Alzheimer's disease, and ALS at the European Society of Gene & Cell Therapy.

When is Dr. Dolmetsch's presentation on Huntington's disease?

Dr. Dolmetsch will present an overview of uniQure's clinical development program for AMT-130 in Huntington's disease on October 20, 2022.

What is the focus of uniQure's gene therapy development?

uniQure focuses on developing gene therapies for severe medical conditions like hemophilia B, Huntington's disease, temporal lobe epilepsy, and Fabry disease.